Company intelligence / Profile preview

Mind Pharmaceuticals

New Haven, Connecticut, United Statesmind-pharma.com ↗

Ownership: Private
Development stage: Other

Overview

Mind Pharmaceuticals is a clinical-stage biotech company developing psychedelic-based therapies for hard-to-treat central nervous system diseases. Their lead asset, MIND001, is an intravenous synthetic DMT formulation for treatment-resistant depression. Early trials show rapid onset and sustained efficacy with a favorable safety profile. Additional pipeline assets target migraine/cluster headache prevention and alcohol use disorder using sub-hallucinogenic doses of psilocybin[1][2][3].

Therapeutic areas: PsychiatryNeurology
Modalities: Small moleculeSynthetic tryptamine (DMT)Psilocybin (sub-hallucinogenic dose)
Industry: Biotech

Drug pipeline

2 assets

MIND003

1 more asset in the full pipeline.

Partnerships

Yale University (licensing of intellectual property and clinical trial collaboration)

Beyond the preview

Go deeper on Mind Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Mind Pharmaceuticals.